| Name | GSK717 |
|---|---|
| Synonyms |
MFCD32671947
N-(2-(1-(2-((2,3-Dihydro-1H-inden-5-yl)ao)-2-oxoethyl)-1H-benzo[D]imidazol-2-yl)ethyl)-N-methylbenzamide immune,GSK717,inhibit,Inhibitor,NOD2-T2,pro-inflammatory,MDP-stimulated,NOD-like Rector (N,responses,cytokines,synergy,GSK 717,GSK-717 1H-Benzimidazole-1-acetamide, 2-[2-(benzoylmethylamino)ethyl]-N-(2,3-dihydro-1H-inden-5-yl) N-(2-(1-(2-((2,3-Dihydro-1H-inden-5-yl)amino)-2-oxoethyl)-1H-benzo[d]imidazol-2-yl)ethyl)-N-methylbenzamide GSK717, 10 mM in DMSO |
| Description | GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells[1]. |
|---|---|
| Related Catalog | |
| In Vitro | GSK717 blocks synergy between NOD2 and TLR2. GSK717 does not affect NOD1, TNFR1 and TLR2-mediated responses. GSK717 (5 μM) inhibits the release of IL-8, IL-6, TNFα and IL-1β in primary human monocytes stimulated with MDP[1]. |
| References |
| Molecular Formula | C28H28N4O2 |
|---|---|
| Molecular Weight | 452.55 |
| Hazard Codes | Xi |
|---|